These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 25648389)

  • 21. [Antidiabetic drugs prescription patterns among a group of patients in Colombia].
    Machado Alba JE; Moncada Escobar JC; Mesa Escobar G
    Rev Panam Salud Publica; 2007 Aug; 22(2):124-31. PubMed ID: 17976279
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Important treatment gaps in vascular protection for the elderly after type 2 diabetes therapy initiation.
    Guénette L; Breton MC; Hamdi H; Grégoire JP; Moisan J
    Can J Cardiol; 2013 Dec; 29(12):1593-8. PubMed ID: 24183301
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Probability of control of the patient with diabetes exclusively treated with pharmacological therapy].
    Villarreal-Ríos E; Paredes-Chaparro A; Martínez-González L; Galicia-Rodríguez L; Vargas-Daza E; Garza-Elizondo ME
    Rev Med Inst Mex Seguro Soc; 2006; 44(4):303-8. PubMed ID: 16904032
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metformin and other glucose-lowering drug initiation and rates of community-based antibiotic use and hospital-treated infections in patients with type 2 diabetes: a Danish nationwide population-based cohort study.
    Mor A; Petersen I; Sørensen HT; Thomsen RW
    BMJ Open; 2016 Aug; 6(8):e011523. PubMed ID: 27543589
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mortality outcomes of different sulphonylurea drugs: the results of a 14-year cohort study of type 2 diabetic patients.
    Bo S; Castiglione A; Ghigo E; Gentile L; Durazzo M; Cavallo-Perin P; Ciccone G
    Eur J Endocrinol; 2013 Jul; 169(1):117-26. PubMed ID: 23660643
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictors of early discontinuation of basal insulin therapy in type 2 diabetes in primary care.
    Kostev K; Dippel FW; Rathmann W
    Prim Care Diabetes; 2016 Apr; 10(2):142-7. PubMed ID: 26324105
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug usage patterns and treatment costs in newly-diagnosed type 2 diabetes mellitus cases, 2007 vs 2012: findings from a large US healthcare claims database analysis.
    Weng W; Liang Y; Kimball ES; Hobbs T; Kong S; Sakurada B; Bouchard J
    J Med Econ; 2016 Jul; 19(7):655-62. PubMed ID: 26855139
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Troglitazone: a review of its use in the management of type 2 diabetes mellitus.
    Plosker GL; Faulds D
    Drugs; 1999 Mar; 57(3):409-38. PubMed ID: 10193691
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sex disparities in treatment patterns after metformin initiation among patients with type 2 diabetes mellitus.
    Oktora MP; de Vos S; de Vries ST; Hak E; Denig P
    Pharmacoepidemiol Drug Saf; 2023 Dec; 32(12):1395-1405. PubMed ID: 37524658
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness and clinical inertia in patients with antidiabetic therapy.
    Machado-Duque ME; Ramírez-Riveros AC; Machado-Alba JE
    Int J Clin Pract; 2017 Jun; 71(6):. PubMed ID: 28524340
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patient-reported outcomes from a 16-week open-label, multicenter study of insulin pump therapy in patients with type 2 diabetes mellitus.
    Rubin RR; Peyrot M; Chen X; Frias JP
    Diabetes Technol Ther; 2010 Nov; 12(11):901-6. PubMed ID: 20879963
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment persistence after initiating basal insulin in type 2 diabetes patients: A primary care database analysis.
    Pscherer S; Chou E; Dippel FW; Rathmann W; Kostev K
    Prim Care Diabetes; 2015 Oct; 9(5):377-84. PubMed ID: 25701545
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The risk of overall mortality in patients with Type 2 diabetes receiving different combinations of sulfonylureas and metformin: a retrospective analysis.
    Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Nutter B; Jain A; Atreja A; Zimmerman RS
    Diabet Med; 2012 Aug; 29(8):1029-35. PubMed ID: 22248043
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Factors associated with early insulin initiation in Type 2 diabetes: a Canadian cross-sectional study.
    Abu-Ashour W; Chibrikova L; Midodzi WK; Twells LK; Gamble JM
    Diabet Med; 2017 Feb; 34(2):229-234. PubMed ID: 26802577
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Initial therapy, persistence and regimen change in a cohort of newly treated type 2 diabetes patients.
    Grimes RT; Bennett K; Tilson L; Usher C; Smith SM; Henman MC
    Br J Clin Pharmacol; 2015 Jun; 79(6):1000-9. PubMed ID: 25521800
    [TBL] [Abstract][Full Text] [Related]  

  • 36. All-Cause and Cardiovascular Mortality following Treatment with Metformin or Glyburide in Patients with Type 2 Diabetes Mellitus.
    Raee MR; Nargesi AA; Heidari B; Mansournia MA; Larry M; Rabizadeh S; Zarifkar M; Esteghamati A; Nakhjavani M
    Arch Iran Med; 2017 Mar; 20(3):141-146. PubMed ID: 28287807
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Persistence patterns with oral antidiabetes drug treatment in newly treated patients--a population-based study.
    Grégoire JP; Sirois C; Blanc G; Poirier P; Moisan J
    Value Health; 2010; 13(6):820-8. PubMed ID: 21054658
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues.
    Pusceddu S; Vernieri C; Di Maio M; Marconcini R; Spada F; Massironi S; Ibrahim T; Brizzi MP; Campana D; Faggiano A; Giuffrida D; Rinzivillo M; Cingarlini S; Aroldi F; Antonuzzo L; Berardi R; Catena L; De Divitiis C; Ermacora P; Perfetti V; Fontana A; Razzore P; Carnaghi C; Davì MV; Cauchi C; Duro M; Ricci S; Fazio N; Cavalcoli F; Bongiovanni A; La Salvia A; Brighi N; Colao A; Puliafito I; Panzuto F; Ortolani S; Zaniboni A; Di Costanzo F; Torniai M; Bajetta E; Tafuto S; Garattini SK; Femia D; Prinzi N; Concas L; Lo Russo G; Milione M; Giacomelli L; Buzzoni R; Delle Fave G; Mazzaferro V; de Braud F
    Gastroenterology; 2018 Aug; 155(2):479-489.e7. PubMed ID: 29655834
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale.
    Casadei Gardini A; Faloppi L; De Matteis S; Foschi FG; Silvestris N; Tovoli F; Palmieri V; Marisi G; Brunetti O; Vespasiani-Gentilucci U; Perrone G; Valgiusti M; Granato AM; Ercolani G; Negrini G; Tamburini E; Aprile G; Passardi A; Santini D; Cascinu S; Frassineti GL; Scartozzi M
    Eur J Cancer; 2017 Nov; 86():106-114. PubMed ID: 28985579
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with glibenclamide as adjunctive therapy in patients with type 2 diabetes poorly controlled on metformin: response to Barnett et al.
    Kanna B; Abreu-Pacheco H
    Diabetes Care; 2007 Feb; 30(2):445-6; author reply 446. PubMed ID: 17259531
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.